Contact
searchSearch
HMP Global
Login
Quiz

Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC

12/17/2025

Related Content

News
LDH and α-HBDH as Prognostic Biomarkers in Extensive-Stage Small Cell Lung Cancer
02/06/2026
Emily Estrada
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early...
02/06/2026
Oncology
News
Multi-Omics Model Accurately Predicts Radiotherapy Response in SCLC Brain Metastases
02/06/2026
Emily Estrada
Results from a retrospective analysis indicate that a multi-omics model integrating clinical, radiomic, and dosiomic features accurately predicts response to whole-brain radiotherapy in patients with small cell lung cancer brain metastases.
Results from a retrospective analysis indicate that a multi-omics model integrating clinical, radiomic, and dosiomic features accurately predicts response to whole-brain radiotherapy in patients with small cell lung cancer brain metastases.
Results from a retrospective...
02/06/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology

Recent News

FDA Approval
FDA Approves Simplified Once-Monthly Amivantamab Plus Hyaluronidase Regimen for First-Line EGFR-Mutated Advanced NSCLC
02/18/2026
Stephanie Holland
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new,...
02/18/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to Subcutaneous Amivantamab in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
02/18/2026
Stephanie Holland
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase...
02/18/2026
Oncology
Inside the 2026 breast cancer program designed to help clinicians interpret rapidly changing data and apply it with confidence in clinical practice.
News
OLN Great Debates: Navigating Evolving Evidence and Treatment Decisions in Breast Oncology
02/17/2026
Kelly McCann, MD, PhD
Inside the 2026 breast cancer program designed to help clinicians interpret rapidly changing data and apply it with confidence in clinical practice.
Inside the 2026 breast cancer program designed to help clinicians interpret rapidly changing data and apply it with confidence in clinical practice.
Inside the 2026 breast cancer...
02/17/2026
Oncology
News
Pirtobrutinib Demonstrates Promise in Relapsed or Refractory Marginal Zone Lymphoma
02/17/2026
Stephanie Holland
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN...
02/17/2026
Oncology
News
Nivolumab Plus Chemotherapy Maintains Survival Advantage in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from...
02/12/2026
Oncology
News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use